1: Are classified by the BNF as 'less suitable for prescribing', and includes anti-malarials (where a private prescription may be provided). Have a lack of data on effectiveness compared with standard therapy
2: Have a lack of data on safety compared with standard therapy
5: Less cost-effective than current standard therapy